Product Description
a P2X3 receptor antagonist with high selectivity
Mechanisms of Action: P2X3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Unexplained Chronic Cough|Refractory Chronic Cough
Phase 1: Healthy Volunteers|Endometriosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03789890 |
NCT03789890 | P1 |
Completed |
Endometriosis |
2019-03-04 |
2019-05-30 |
Study Completion Date|Treatments|Trial Status |
|
NCT03212586 |
BAY 1902607 | P1 |
Completed |
Healthy Volunteers |
2018-05-03 |
2019-03-21 |
Treatments |
|
NCT03535168 |
NCT03535168 | P2 |
Completed |
Refractory Chronic Cough|Unexplained Chronic Cough |
2019-09-25 |
2019-11-05 |
Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/21/2019 |
News Article |
Chronic Refractory Cough (CRC) Market Insights, Epidemiology, and Market Forecasts, 2028 |
|
09/17/2019 |
News Article |
Global Chronic Refractory Cough Pipeline Insight Report 2019 - ResearchAndMarkets.com |